Quick Answer
Alaunos Therapeutics, Inc. reported Net Income of -$4.18 million for fiscal year 2025.
Alaunos Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$4.18M | +10.8% |
| 2024 | -$4.68M | +0.0% |
| 2023 | -$4.68M | +87.6% |
| 2022 | -$37.73M | +52.1% |
| 2021 | -$78.75M | +1.5% |
| 2020 | -$79.98M | +32.1% |
| 2019 | -$117.80M | -121.8% |
| 2018 | -$53.12M | +2.2% |
| 2017 | -$54.32M | +67.1% |
| 2016 | -$165.30M | -37.6% |
| 2015 | -$120.09M | -277.9% |
| 2014 | -$31.78M | +44.3% |
| 2013 | -$57.11M | +40.6% |
| 2012 | -$96.13M | -50.7% |
| 2011 | -$63.78M | -95.2% |
| 2010 | -$32.67M | -327.1% |
| 2009 | -$7.65M | +69.7% |
| 2008 | -$25.23M | +5.2% |
| 2007 | -$26.61M | -49.0% |
| 2006 | -$17.86M | -87.6% |
| 2005 | -$9.52M | -67.3% |
| 2004 | -$5.69M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.16M | -2.8% | -10.3% |
| June 30, 2025 | -$1.05M | +6.9% | +2.1% |
| March 31, 2025 | -$1.07M | +36.2% | +4.8% |
| September 30, 2024 | -$1.13M | +86.7% | +0.2% |
| June 30, 2024 | -$1.13M | +87.1% | +32.9% |
| March 31, 2024 | -$1.68M | +83.3% | +80.2% |
| September 30, 2023 | -$8.48M | +4.2% | +3.4% |
| June 30, 2023 | -$8.77M | +11.7% | +12.7% |
- Alaunos Therapeutics, Inc. showed an increase of +10.8% in Net Income compared to the prior fiscal year.
- Over the 2004–2025 period, Alaunos Therapeutics, Inc.’s net income has grown by 26.6% (from -$5.69 million to -$4.18 million).
- The most recent figure is from Alaunos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: